Sermorelin
← All compounds
FDA-Approved WADA BANNED

Sermorelin

Geref® (discontinued)
Muscle & performanceSleep qualityLongevity
RouteSubcutaneous injection (daily, at bedtime)
+ Add to plan

Mechanism

A GHRH analog, just the first 29 residues of the real thing, and that is apparently all your pituitary needs to hear. It releases its own growth hormone, on its own feedback loop, the way it was always designed to.

Key Benefit

Improves body composition, sleep quality, and skin elasticity. Original FDA approval was for GH deficiency diagnostics; clinical use expanded.

Evidence Base

This one was FDA-approved once. Geref, 1997, strictly for diagnosing GH deficiency. It got pulled for money reasons, not safety, and that distinction matters. Compounding pharmacies never stopped making it.

Route & Rationale

Subcutaneous injection (daily, at bedtime). Peptide requires SC delivery. Bedtime dosing matches nocturnal GH pulse physiology.

Interactions

Monitor IGF-1. May interact with glucocorticoids (blunt GH response).

Regulatory Status

Previously FDA-approved, pulled from the market for business reasons, nothing about safety. You can still get it through compounding pharmacies. WADA has it flagged as a GH secretagogue, banned same as the rest of that family.

Hard Contraindications

Cancer (active/history), Pregnancy/planning